Download

full announcement

UK
19 Dec 2019 13:01 CET

University of Virginia Center for Diabetes Technology and Novo Nordisk enter into research collaboration to develop virtual patient modelling for type 2 diabetes

Charlottesville, Virginia, US and Bagsværd, Denmark 19 December 2019 – University of Virginia (UVA) Center for Diabetes Technology and Novo Nordisk today announced that they have entered into a five-year research collaboration where UVA and Novo Nordisk will work together on the development of virtual environments focused on modelling of patients with type 2 diabetes.

The goal of the collaboration is to enable simulation of the human metabolic system of different types of individual people with type 2 diabetes and simulating virtual patient populations. The research collaboration will utilise UVA’s work within diabetes and extensive knowledge on patient simulation and data-driven models within diabetes.  Aligned with Novo Nordisk’s digital therapeutics strategy, the research collaboration will initially focus on establishing a ‘virtual innovation lab’ between Novo Nordisk and University of Virginia Center for Diabetes Technology to gain a deep understanding of type 2 diabetes for the purpose of enabling virtual simulation.

“We are pleased to announce our collaboration with UVA’s Center for Diabetes Technology whose demonstrated capabilities in virtual patient modelling will help enable us to create a highly differentiated approach to the treatment of type 2 diabetes,” said Kenneth Strømdahl, senior vice president for Device R&D in Novo Nordisk. “This important research collaboration reflects Novo Nordisk’s enduring commitment to innovation within the area of digital therapeutics and changing the lives for people living with type 2 diabetes.”

“UVA has made solid progress in understanding and quantifying the physiological pathways and treatment behaviour related to diabetes,” said Boris Kovatchev, PhD, director of University of Virginia Center for Diabetes Technology. “We believe this technology has the potential to assist the design of advisory and automated support systems, and we are looking forward to working with Novo Nordisk to extend our research into improving care for patients with type 2 diabetes through data-driven models, analytics, computer simulation and artificial intelligence.”

UVA and Novo Nordisk will initially dedicate around 15 employees to the collaboration and expect the support to grow as the research develops.

About UVA Center for Diabetes Technology

The UVA Center for Diabetes Technology advances the use of technology, including analytics, to allow improved management, monitoring and therapies for patients with diabetes. The Center is a recognized world leader in the technological treatment of diabetes and a hub of an international research network of leading U.S. institutions and research groups in Italy, France, and Argentina.

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,200 people in 80 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information

Media UVA   
Eric Swensen+1 434.924.5770EWS3J@hscmail.mcc.virginia.edu
   
Media Novo Nordisk  
Mette Kruse Danielsen+45 3079 3883mkd@novonordisk.com
Ken Inchausti (US)+1 609 240 9429kiau@novonordisk.com
   
Investor relations Novo Nordisk  
Peter Hugreffe Ankersen+45 3075 9085phak@novonordisk.com
Valdemar Borum Svarrer+45 3079 0301jvls@novonordisk.com
Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com
Mark Joseph Root+45 3079 4211mjhr@novonordisk.com
Kristoffer Due Berg (US)(US) +1 609 235 2989krdb@novonordisk.com


Attachment